Patent ID: 8835634
Filing Date: 2014-09-16
Classification: A61P,C07D

Abstract:
1. A method for modulating insulin secretion in insulin-1 cells comprising contacting the cells with a compound selected from the following compounds: 1-(2,2-difluoroethyl)-3-phenyl-quinoxalin-2(1H)-one; 3-(4-chlorophenyl)-1-(2,2-difluoroethyl)quinoxalin-2(1H)-one; 3-(4-chlorophenyl)-1-cyclopropyl-quinoxalin-2(1H)-one; 1-butyl-3-(4-fluorophenyl)quinoxalin-2(1H)-one; 3-(4-fluorophenyl)-1-(2,2,2-trifluoroethyl)quinoxalin-2(1H)-one; 1,3-diethyl-5-fluoro-quinoxalin-2(1H)-one; 1-ethyl-7-methyl-3-propyl-quinoxalin-2(1H)-one; 1-ethyl-3-butyl-quinoxalin-2(1H)-one; 1-ethyl-6,7-difluoro-3-(4-fluorophenyl)quinoxalin-2(1H)-one; 1-ethyl-6,7-difluoro-3-(4-chlorophenyl)quinoxalin-2(1H)-one; 1-cyclopropyl-3-phenylquinoxalin-2(1H)-one; 1-ethyl-3-furan-2-yl-quinoxalin-2(1H)-one; 1-ethyl-5-fluoro-3-(4-fluorophenyl)quinoxalin-2(1H)-one; 1-cyclopropyl-3-(4-fluorophenyl)quinoxalin-2(1H)-one; 1-butyl-3-(4-chlorophenyl)quinoxalin-2(1H)-one; 1-butyl-3-phenyl-quinoxalin-2(1H)-one; 3-(4-chlorobenzyl)-1-ethyl-quinoxalin-2(1H)-one; 3-(4-chlorophenyl)-1-(2,2,2-trifluoroethyl)quinoxalin-2(1H)-one; 3-phenyl-1-(2,2,2-trifluoroethyl)quinoxalin-2(1H)-one; 1-(2,2,2-trifluoroethyl)-3-(4-trifluoromethylphenyl)quinoxalin-2(1H)-one; 1-cyclopropylmethyl-3-ethyl-quinoxalin-2(1H)-one; 1-ethyl-3-isopropyl-7-methyl-quinoxalin-2(1H)-one; 1-ethyl-5-fluoro-3-isobutyl-quinoxalin-2(1H)-one; 1,3-diethyl-6,7-difluoro-quinoxalin-2(1H)-one; 1-(2,2-difluoroethyl)-3-ethylquinoxalin-2(1H)-one; 1,3-diethyl-5-fluoroquinoxalin-2(1H)-one; 1,3-diethyl-7-methylquinoxalin-2(1H)-one; 1-ethyl-5-fluoro-3-propylquinoxalin-2(1H)-one; 1-butyl-3-ethylquinoxalin-2(1H)-one; 3-butyl-1-ethylquinoxalin-2(1H)-one; 1-ethyl-3-isobutyl-7-methylquinoxalin-2(1H)-one; 1-cyclopropyl-3-propylquinoxalin-2(1H)-one; 1-cyclopropyl-3-ethylquinoxalin-2(1H)-one; 1,3-diethyl-quinoxalin-2(1H)-one; 1-(2,2-difluoroethyl)-3-(4-fluorophenyl)quinoxalin-2(1H)-one; 3-(4-chlorophenyl)-1-ethyl-5-fluoroquinoxalin-2(1H)-one; 3-(4-chlorophenyl)-1-ethyl-quinoxalin-2(1H)-one; 3-(2-chlorophenyl)-1-ethyl-quinoxalin-2(1H)-one; 1-ethyl-3-(4-fluorophenyl)quinoxalin-2(1H)-one; 1-ethyl-3-(4-methylphenyl)quinoxalin-2(1H)-one; 1-ethyl-3-(4-fluoro-2-methylphenyl)quinoxalin-2(1H)-one; 1-ethyl-3-(4-chloro-2-methylphenyl)quinoxalin-2(1H)-one; 1-ethyl-3-(4-trifluoromethylphenyl)quinoxalin-2(1H)-one; 1-ethyl-3-(4-methanesulfonyl-phenyl)quinoxalin-2(1H)-one; 3-(2,4-dimethoxy-pyrimidin-5-yl)-1-ethyl-quinoxalin-2(1H)-one; 1-ethyl-3-(4-ethylphenyl)quinoxalin-2(1H)-one; 1-ethyl-3-furan-3-yl-quinoxalin-2(1H)-one; 3-(3,4-dimethoxyphenyl)-1-ethyl-quinoxalin-2(1H)-one; 4-(4-ethyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-benzoic acid; 1-ethyl-3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-2(1H)-one; 3-(3-chlorophenyl)-1-ethyl-quinoxalin-2(1H)-one; 1-ethyl-3-pyridin-3-yl-quinoxalin-2(1H)-one; 3-(2,5-difluorophenyl)-1-ethyl-quinoxalin-2(1H)-one; 1-ethyl-3-(1H-indo1-6-yl)quinoxalin-2(1H)-one; 1-ethyl-3-(1H-indo1-5-yl)quinoxalin-2(1H)-one; 1-ethyl-3-(4-methylbenzyl)quinoxalin-2(1H)-one; 1-ethyl-3-(4-morpholin-4-ylphenyl)quinoxalin-2(1H)-one; 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-ethylquinoxalin-2(1H)-one; 3-(1,3-benzodioxo1-5-yl)-1-ethylquinoxalin-2(1H)-one; 1-ethyl-3-benzylquinoxalin-2(1H)-one; 1-ethyl-3-{[(4-methylphenyl)thio]methyl}quinoxalin-2(1H)-one; 1-ethyl-3-{[(4-methylphenyl)sulfonyl]methyl}quinoxalin-2(1H)-one; 3-{[(4-chlorophenyl) sulfonyl]methyl}-1-methyl-quinoxalin-2(1H)-one; 1-ethyl-3-{[(4-methoxyphenyl)sulfonyl]methyl}quinoxalin-2(1H)-one; 1-methyl-3-[(phenylsulfonyl)methyl]quinoxalin-2(1H)-one; 1-ethyl-3-[(phenylsulfonyl)methyl]quinoxalin-2(1H)-one; 3-{[(4-chlorobenzyl)sulfonyl]methyl}-1-ethylquinoxalin-2(1H)-one; and 3-[(benzylsulfonyl)methyl]-1-ethylquinoxalin-2(1H)-one; or a racemic form, tautomer, enantiomer, diastereomer or epimer thereof, or mixtures thereof, or pharmaceutically acceptable salt thereof.